Skip to content

The New Kids on the Block: Evaluation of Novel Hyperlipidemia Medications

New medications to treat hyperlipidemia with novel mechanisms of action have been introduced to the market over the past few years but current practice does not take all available cholesterol medications into consideration when developing treatment plans. Familiarity with available novel therapies positions a pharmacist to recommend the best available therapeutic options when working with providers and patients to treat hyperlipidemia. It is anticipated that updates to the 2018 cholesterol guidelines will include all available therapies and emphasize individualized treatment to achieve optimal clinical outcomes.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Explain the mechanism of action of novel lipid-lowering drugs as they relate to the cholesterol life cycle
  • Identify indications, contraindications, drug-drug interactions, and key counseling points for novel lipid-lowering drugs
  • Summarize key lipid-lowering and cardiovascular outcomes from recent clinical trials
  • Given a patient case, provide pharmacotherapeutic recommendations related to lipid-lowering medications


Morgan Harris, PharmD
Morgan Harris, PharmD graduated from Creighton University School of Pharmacy and Health Professions in May 2020. She is currently in her first year of a Post-Doctoral fellowship through MCPHS in Clinical Operations- General Medicine at Novartis.

Pourya Pourhosseini, PharmD, RPh
Pourya Pourhosseini, PharmD, RPh received his Bachelor of Science in bioengineering from the University of California San Diego and his Doctor of Pharmacy from Skaggs School of Pharmacy and Pharmaceutical Sciences in San Diego. He has a background in pharmacokinetic modeling and pharmacy informatics. In 2020, Dr. Pourhosseini joined Novartis Institute for Biomedical Research (NIBR) as a Post-Doctoral fellow in clinical operation. He also holds an adjunct faculty position at Massachusetts College of Pharmacy and Health Sciences.

Registration Fee: Free to MCPHS alumni and employees; $12.00 for all other professionals.


ACPE logo 

Release Date: February 26, 2021
Expiration Date: February 26, 2022
Contact Hours: 1.0
ACPE 0026-0000-21-209-H01-P | Knowledge-based
ACPE Topic Designator: Disease State Management/Drug Therapy


MCPHS University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1 contact hour (0.01 CEUs).

Requirements for Credit

In order to receive credit, the participant must review the entire presentation and complete the post-test and evaluation form. Upon completion, participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.

Statement of Disclosure

MCPHS University adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS University that the speakers and planning committee disclose real or apparent conflicts of interest relating to the topics of the educational activity, that relevant conflicts of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drugs or devices during their presentation.

No funding from ineligible companies was provided for the development of this educational module. No exhibitors will be present.
Morgan Harris and Pourya Pourhosseini do not hold relevant financial relationships with ineligible companies.
MCPHS-CE staff does not hold relevant financial relationships with ineligible companies.